-
公开(公告)号：US20190070163A1
公开(公告)日：2019-03-07
申请号：US16183352
申请日：2018-11-07
发明人： Masao SUGAMATA
IPC分类号： A61K31/47 , G01N33/50 , A61K45/06 , A61K31/381 , A61K31/41 , A61K31/404
摘要： Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
-
公开(公告)号：US10149846B2
公开(公告)日：2018-12-11
申请号：US15680493
申请日：2017-08-18
发明人： Masao Sugamata
IPC分类号： A61K31/47 , G01N33/50 , A61K45/06 , A61K31/381 , A61K31/41 , A61K31/404
摘要： Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
-
公开(公告)号：US10729683B2
公开(公告)日：2020-08-04
申请号：US16183352
申请日：2018-11-07
发明人： Masao Sugamata
IPC分类号： A61K31/47 , A61K31/381 , A61K31/404 , A61K31/41 , A61K45/06 , G01N33/50
摘要： Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
-
公开(公告)号：US09775836B2
公开(公告)日：2017-10-03
申请号：US14786089
申请日：2014-04-22
发明人： Masao Sugamata
IPC分类号： A61K31/47 , A61K31/381 , A61K31/404 , A61K31/41 , A61K45/06 , G01N33/50
CPC分类号： A61K31/47 , A61K31/381 , A61K31/404 , A61K31/41 , A61K45/06 , G01N33/5011
摘要： Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
-
公开(公告)号：US20160058748A1
公开(公告)日：2016-03-03
申请号：US14786089
申请日：2014-04-22
发明人： Masao SUGAMATA
IPC分类号： A61K31/47 , G01N33/50 , A61K31/381 , A61K31/404 , A61K31/41
CPC分类号： A61K31/47 , A61K31/381 , A61K31/404 , A61K31/41 , A61K45/06 , G01N33/5011
摘要： Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
摘要翻译： 公开了对癌症的治疗，预防等有效并具有较少副作用的药物。 本发明的抗肿瘤剂包含至少一种白细胞三烯抑制剂作为有效成分。 白细胞三烯抑制剂的实例包括白三烯产生抑制剂和白三烯受体拮抗剂，白三烯抑制剂的优选具体实例包括孟鲁司特，扎非司酮，普鲁司特和齐鲁顿; 这些化合物的药学上可接受的盐; 和这些化合物的药学上可接受的溶剂化物和盐。 白细胞三烯抑制剂也可用作伴随肿瘤的疼痛的缓解剂，以及作为基质增生抑制剂。
-
公开(公告)号：US20170348299A1
公开(公告)日：2017-12-07
申请号：US15680493
申请日：2017-08-18
发明人： Masao SUGAMATA
IPC分类号： A61K31/47 , A61K31/41 , A61K31/381 , A61K31/404 , G01N33/50 , A61K45/06
CPC分类号： A61K31/47 , A61K31/381 , A61K31/404 , A61K31/41 , A61K45/06 , G01N33/5011
摘要： Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.013 秒)
